Implanet Sa - IMPZY STOCK NEWS

IMPLANET, a medical technology company, has received FDA 510(k) clearance for its Squale anterior cervical cage, marking a significant step in its U.S. expansion strategy. The Squale cage, designed for optimal interbody fusion and suitable for vertebral anatomy, has already seen over 15,000 implants globally. This clearance follows earlier surgeries in the U.S. with the ORIGIN cervical plate in 2022. CEO Ludovic Lastennet emphasized that this development aligns with their goal to reinforce their presence in the estimated $1.35 billion U.S. spinal surgery market. The marketing launch is expected before summer 2023. IMPLANET will also release its 2023 First-Quarter Revenue on April 25, post-market close.

Implanet (Euronext: ALIMP) reported a 31% increase in annual revenue for 2022, totaling €8.03 million compared to €6.14 million in 2021. Notable growth occurred across various markets, with revenue in the United States soaring 181% in Q4 2022. The JAZZ® platform achieved record unit sales, up 31%, while export activities across all quarters showed strong momentum. Despite a 9% decline in Q4 2022 revenue in France, anticipated financial support from partnerships, including €2.5 million from Sanyou Medical, aims to fund future developments. As of December 31, 2022, the company's cash position stood at €0.5 million.

IMPLANET, a medical technology company focused on vertebral implants, has announced its upcoming financial information schedule for 2023. Key dates include the publication of 2022 Full-Year Revenue on January 24, 2023 and 2022 Full-Year Results on March 7, 2023. The Annual General Meeting is set for April 18, 2023, with first-quarter revenue expected on April 25, 2023. IMPLANET operates within the orthopedic surgery sector and has been expanding its commercial presence in the U.S.

IMPLANET has signed an exclusive distribution agreement with SMTP Technology Co. for its ultrasonic surgical scalpel in France. This partnership aims to enhance surgical efficiency and patient safety, leveraging IMPLANET's established presence in the French medical market. The scalpel offers innovative design features and has received marketing approval in China, the EU, and the US. This agreement follows IMPLANET's recent strategic repositioning in the spine market, indicating a focused effort on growth and innovation in the orthopedic sector.

Implanet has signed a distribution agreement for its JAZZ® platform in China and established a technology partnership with Sanyou Medical. This collaboration, following a previous capital increase, positions Implanet to leverage Sanyou’s market leadership to access China’s vast spine surgery market, which performs approximately 765,000 surgeries annually. The agreement also aims to develop a new European hybrid fixation system utilizing advanced technologies like robotics and artificial intelligence.

IMPLANET reported strong revenue growth for Q3 2022 and the first nine months, with total revenues rising to €1.86M for the quarter, up 5% year-over-year, and €5.97M year-to-date, reflecting a 37% increase. Growth was driven by a 17% increase in the U.S. market and a 13% increase in the rest of the world, despite challenges in France. The company successfully raised €2.77M through a capital increase and has a solid cash position of €2.8M to support its expansion in China and R&D investments.

Implanet has successfully raised €2.77 million through the issuance of 9,879,254 shares with warrants, reflecting strong shareholder support. This capital increase also includes a 28.96% acquisition stake by Sanyou Medical. The funds will be utilized to expand sales of the JAZZ® range in China and enhance R&D efforts. Sanyou Medical plans to exercise warrants for an additional €2.5 million, potentially increasing its stake to 43.19%. Despite the optimistic outlook, the company faces liquidity and volatility risks regarding its stock performance.

IMPLANET reported a substantial revenue increase of 58% to €4.1 million in H1 2022 compared to the previous year. Gross margin also grew by 52% to €2.6 million. The company has removed conditions for a €5 million capital increase backed by Sanyou Medical, enhancing financial stability. Despite the positive revenue growth, the operating loss widened to €2.19 million.

IMPLANET is focused on expanding its spine business, particularly in the Chinese market, while managing increased operational costs.

IMPLANET announces the successful fulfillment of conditions for its partnership with Sanyou Medical, which will allow for the implementation of a €5 million investment. This partnership aims to leverage technological and commercial synergies in spine surgery, with a distribution agreement pending approval from Chinese health authorities. A planned capital increase of approximately €5.5 million will be open to all shareholders and is expected to occur before October 31, 2022. The final agreements will be concluded by December 31, 2022.